Interventional study on the reduction of thrombus using rivaroxaban for deep vein thrombosis and pulmonary thromboembolism

Interventional study on the reduction of thrombus using rivaroxaban for deep vein thrombosis and pulmonary thromboembolism - Interventional study on the reduction of thrombus using rivaroxaban for deep vein thrombosis and pulmonary thromboembolism

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032996

Enrollment

Registered

2018-06-15

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

venous thromboembolism

Interventions

contrast CT examination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with acute symptomatic VTE,and patients with asymptomatic VTE who were considered that it is necessary to receive treatment

Exclusion criteria

Exclusion criteria: under18 years old,massive or submassive PTE patients,patients with active bleeding,patients had CCr under 30ml/min

Design outcomes

Primary

Measure	Time frame
the reduction of venous thrombus 1week,3 weeks, 3 months later after start of the treatment	—

Countries

Japan

Contacts

Public ContactShinji Hisatake

Toho University Faculty of Medicine Department of Cardiovascular Medicine

s-hisatake@med.toho-u.ac.jp0337624151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026